RO 7656594
Alternative Names: GDC 2992; RG-6537; RO-7656594Latest Information Update: 26 Apr 2023
At a glance
- Originator Genentech
- Class Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor degradation enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 14 Apr 2023 Phase-I clinical trials in Prostate cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT05800665)
- 05 Apr 2023 Preclinical trials in Prostate cancer in USA (PO)
- 05 Apr 2023 Genentech plans a phase I trial for Prostate cancer (Late stage disease, Metastatic disease, Second-line therapy) in March 2023 (PO) (NCT05800665)